株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EpiCast Report:慢性リンパ性白血病の疫学的予測

EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2025

発行 GlobalData 商品コード 301138
出版日 ページ情報 英文 47 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.76円で換算しております。
Back to Top
EpiCast Report:慢性リンパ性白血病の疫学的予測 EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2025
出版日: 2017年11月01日 ページ情報: 英文 47 Pages
概要

慢性リンパ性白血病(CLL、慢性リンパ様白血病)とは、白血球(リンパ球)のがんの一種で、特定のリンパ球(B細胞)−−主に骨髄・血液内に集積し、感染症と闘う細胞です−−に悪影響を及ぼします。CLLは西欧諸国では一般的な白血病の形態で、年間平均発症率は人口10万人当たり5.0件(年齢問わず)となっています。基本的には高齢者が発症する疾患であり、40歳以下の患者の割合は10%以下となっています。世界の主要6ヶ国における発症件数は、2013年の37,795件から、2023年には45,683にまで増加する見通しで、その年平均成長率(CAGR)は2.09%と推計されています。また、治療済みの有病者数も、2013年の150,800人から、2023年には183,165にまで増加すると見られています(年平均成長率(CAGR)は2.15%)。

当レポートでは、世界の主要6ヶ国(米国・フランス・ドイツ・イタリア・スペイン・英国)における慢性リンパ性白血病(CLL)の発症状況や今後の見通しについて分析し、疾患の特徴(リスク要因や主な共存症など)や世界各国での動向、現在の有病者の発症状況、今後10年間の発症・有病件数の予測値などを調査・推計して、その結果を概略以下の内容でお届けいたします。

第1章 目次

第2章 イントロダクション

  • 概要
  • 近日刊行の関連調査

第3章 疫学

  • 疾患の背景
  • リスク要因と共存症
  • 世界的な傾向
    • 発症件数
    • 生存率:米国・欧州5ヶ国の場合
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法:診断された発症件数
    • 予測の前提条件と手法:診断された有病者数(今後5年間分)
    • 予測の前提条件と手法:診断時のRai分類
  • 慢性リンパ性白血病(CLL)の疫学予測(今後11年間分)
    • 診断された発症件数
    • 診断された発症件数(年齢別)
    • 診断された発症件数(性別)
    • 診断された発症件数(年齢調整済み)
    • 診断された発症件数(診断時のRai分類別)
    • 診断された有病者数:今後5年間の予測
  • 議論
    • 疫学的な予測に関する結論
    • 分析の限界
    • 分析の強み

第4章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHCER164-17

Chronic lymphocytic leukemia (CLL), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection. In CLL, the DNA of a B cell is damaged so that it cannot fight infection, but instead, it grows out of control and affects the healthy blood cells that can fight infection (NCI, 2016). CLL is closely related to small lymphocytic lymphoma (SLL), a type of non-Hodgkin's lymphoma that presents primarily in the lymph nodes.

In the 7MM, epidemiologists forecast an increase in the diagnosed incident cases of CLL from 40,631 diagnosed incident cases in 2015 to 49,643 diagnosed incident cases in 2025, with an annual growth rate (AGR) of 2.22% during the forecast period. The US will have the highest number of diagnosed incident cases of CLL among the 7MM throughout the forecast period, while Spain will have the lowest.

The report "EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2025" provides an overview of the risk factors, comorbidities, and the global and historical trends for CLL in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Canada). The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CLL segmented by age (for ages 18 years and older) and sex. Additionally, the CLL diagnosed incident cases are segmented by Rai and Binet stage at diagnosis, symptom status (symptomatic vs. asymptomatic), and immunoglobulin heavy chain variable (IGHV) region gene mutation status (mutated vs. unmutated) for the 7MM.

Scope

  • The Chronic lymphocytic leukemia (CLL) EpiCast Report provides an overview of the risk factors and global trends of CLLin the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CLL and five-year diagnosed prevalent cases of CLL. Incident cases are segmented by age, sex, Rai and Binet stage at diagnosis, symptom status (symptomatic vs. asymptomatic), and immunoglobulin heavy chain variable (IGHV) region gene mutation status (mutated vs. unmutated) for the 7MM. The diagnosed incident cases of CLL with the mutations 17p deletion, 11q deletion, and TP53 are also provided in the report.
  • The CLL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The CLL EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global CLL market.
  • Quantify patient populations in the global CLL market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CLL therapeutics in each of the markets covered.
  • Understand magnitude of CLL population by two staging systems.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 4

2 Executive Summary 5

  • 2.1 Related Reports 8
  • 2.2 Upcoming Reports 8

3 Epidemiology 9

  • 3.1 Disease Background 9
  • 3.2 Risk Factors and Comorbidities 10
  • 3.3 Global and Historical Trends 11
  • 3.4 Forecast Methodology 13
    • 3.4.1 Sources 14
    • 3.4.2 Forecast Assumptions and Methods 21
    • 3.4.3 Diagnosed Incident Cases 22
    • 3.4.4 Diagnosed Incident Cases by Stage at Diagnosis (Rai Staging) 24
    • 3.4.5 Diagnosed Incident Cases by Stage at Diagnosis (Binet Staging) 24
    • 3.4.6 Diagnosed Incident Cases by Disease Symptom Status 25
    • 3.4.7 Mutations (17p deletion, 11q Deletion, and TP53) Among the Diagnosed Incident Cases of CLL 25
    • 3.4.8 IGHV Mutation Among Diagnosed Incident Cases of CLL 27
    • 3.4.9 Five-Year Diagnosed Prevalent Cases of CLL 28
  • 3.5 Epidemiological Forecast for CLL (2015-2025) 29
    • 3.5.1 Diagnosed Incident Cases of CLL 29
    • 3.5.2 Age-Specific Diagnosed Incident Cases of CLL 30
    • 3.5.3 Sex-Specific Diagnosed Incident Cases of CLL 31
    • 3.5.4 Diagnosed Incident Cases of CLL by Stage at Diagnosis (Rai Staging) 32
    • 3.5.5 Diagnosed Incident Cases of CLL by Stage at Diagnosis (Binet Staging) 33
    • 3.5.6 Diagnosed Incident Cases of CLL by Disease Symptom Status 34
    • 3.5.7 Diagnosed Incident Cases of CLL with 17p Deletion 35
    • 3.5.8 Diagnosed Incident Cases of CLL with 11q Deletion 36
    • 3.5.9 Diagnosed Incident Cases of CLL with TP53 Mutation 37
    • 3.5.10 Diagnosed Incident Cases of CLL by IGHV Mutation Status 38
    • 3.5.11 Five-Year Diagnosed Prevalent Cases of CLL 38
  • 3.6 Discussion 39
    • 3.6.1 Epidemiological Forecast Insight 39
    • 3.6.2 Limitations of Analysis 40
    • 3.6.3 Strengths of Analysis 40

4 Appendix 42

  • 4.1 Bibliography 42
  • 4.2 About the Authors 45
    • 4.2.1 Epidemiologist 45
    • 4.2.2 Reviewers 45
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 46
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 46
  • 4.3 About GlobalData 47
  • 4.4 Contact Us 47
  • 4.5 Disclaimer 47

List of Tables

1.1 List of Tables

  • Table 1: CLL Clinical Stages 10
  • Table 2: Risk Factors and Comorbidities for CLL 11
  • Table 3: 7MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥18 Years, Selected Years 2015-2025. 29
  • Table 4: 7MM, Five-Year Diagnosed Prevalent Cases of CLL, Both Sexes, Ages ≥18 Years, Selected Years 2015-2025 39

List of Figures

1.2 List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥18 Years, 2015 and 2025 6
  • Figure 2: 7MM, Five-Year Diagnosed Prevalent Cases of CLL, Both Sexes, Ages ≥18 Years , 2015 and 2025 7
  • Figure 3: 7MM, CLL Age-Standardized Diagnosed Incidence (Cases per 100,000 Population), Men, Ages ≥18 Years, 2005 to 2025 12
  • Figure 4: 7MM, CLL Age-Standardized Diagnosed Incidence (Cases per 100,000 Population), Women, Ages ≥18 Years, 2005 to 2025 13
  • Figure 5: 7MM, Sources Used, Diagnosed Incident Cases of CLL 14
  • Figure 6: 7MM, Sources Used, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Rai Staging) 15
  • Figure 7: 7MM, Sources Used, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Binet Staging) 16
  • Figure 8: 7MM, Sources Used, 17p Deletion Among the Diagnosed Incident Cases of CLL 17
  • Figure 9: 7MM, Sources Used, 11q Deletion Among the Diagnosed Incident Cases of CLL 18
  • Figure 10: 7MM, Sources Used, TP53 Mutation Among the Diagnosed Incident Cases of CLL 19
  • Figure 11: 7MM, Sources Used, Diagnosed Incident Cases of CLL by IGHV Mutation Status 20
  • Figure 12: 7MM, Sources Used and Not Used, Five-Year Diagnosed Prevalent Cases of CLL 21
  • Figure 13: 7MM, Age-Specific Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥18 Years, 2015 30
  • Figure 14: 7MM, Sex-Specific Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥18 Years, 2015 31
  • Figure 15: 7MM, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Rai Staging), Both Sexes, Ages ≥18 Years, 2015 32
  • Figure 16: 7MM, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Binet Staging), Both Sexes, Ages ≥18 Years, 2015 33
  • Figure 17: 7MM, Diagnosed Incident Cases of CLL by Disease Symptom Status, Both Sexes, Ages ≥18 Years, 2015 34
  • Figure 18: 7MM, Diagnosed Incident Cases of CLL with 17p Deletion, Both Sexes, Ages ≥18 Years, 2015 35
  • Figure 19: 7MM, Diagnosed Incident Cases of CLL with 11q Deletion, Both Sexes, Ages ≥18 Years, 2015 36
  • Figure 20: 7MM, Diagnosed Incident Cases of CLL with TP53 Mutation, Both Sexes, Ages ≥18 Years, 2015 37
  • Figure 21: 7MM, Diagnosed Incident Cases of CLL by IGHV Mutational Status, Both Sexes, Ages ≥18 Years, 2015 38
Back to Top